File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer

TitlePotential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer
Authors
KeywordsGastric cancer promoter hypermethylation
Oncogenes
Tumour suppressor genes
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
Citation
British Journal Of Cancer, 2005, v. 92 n. 12, p. 2190-2194 How to Cite?
AbstractWhile there is no reliable serum biomarker for the diagnosis and monitoring of patients with gastric cancer, we tested the potential diagnostic and prognostic values of detecting methylation changes in the serum of gastric cancer patients. DNA was extracted from the pretherapeutic serum of 60 patients with confirmed gastric adenocarcinoma and 22 age-matched noncancer controls. Promoter hypermethylation in 10 tumour-related genes (APC, E-cadherin, GSTP1, hMLH1, MGMT, p15, p16, SOCS1, TIMP3 and TGF-beta RII) was determined by quantitative methylation-specific PCR (MethyLight). Preferential methylation in the serum DNA of gastric cancer patients was noted in APC (17%), E-cadherin (13%), hMLH1 (41%) and TIMP3 (17%) genes. Moreover, patients with stages III/IV diseases tended to have higher concentrations of methylated APC (P = 0.08), TIMP3 (P = 0.005) and hMLH1 (P = 0.03) in the serum. In all, 33 cancers (55%) had methylation detected in the serum in at least one of these four markers, while three normal subjects had methylation detected in the serum (specificity 86%). The combined use of APC and E-cadherin methylation markers identified a subgroup of cancer patients with worse prognosis (median survival 3.3 vs 16.1 months, P = 0.006). These results suggest that the detection of DNA methylation in the serum may carry both diagnostic and therapeutic values in gastric cancer patients. © 2005 Cancer Research UK.
Persistent Identifierhttp://hdl.handle.net/10722/162861
ISSN
2023 Impact Factor: 6.4
2023 SCImago Journal Rankings: 3.000
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, WKen_US
dc.contributor.authorTo, KFen_US
dc.contributor.authorChu, ESHen_US
dc.contributor.authorChan, MWYen_US
dc.contributor.authorBai, AHCen_US
dc.contributor.authorNg, EKWen_US
dc.contributor.authorChan, FKLen_US
dc.contributor.authorSung, JJYen_US
dc.date.accessioned2012-09-05T05:24:31Z-
dc.date.available2012-09-05T05:24:31Z-
dc.date.issued2005en_US
dc.identifier.citationBritish Journal Of Cancer, 2005, v. 92 n. 12, p. 2190-2194en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttp://hdl.handle.net/10722/162861-
dc.description.abstractWhile there is no reliable serum biomarker for the diagnosis and monitoring of patients with gastric cancer, we tested the potential diagnostic and prognostic values of detecting methylation changes in the serum of gastric cancer patients. DNA was extracted from the pretherapeutic serum of 60 patients with confirmed gastric adenocarcinoma and 22 age-matched noncancer controls. Promoter hypermethylation in 10 tumour-related genes (APC, E-cadherin, GSTP1, hMLH1, MGMT, p15, p16, SOCS1, TIMP3 and TGF-beta RII) was determined by quantitative methylation-specific PCR (MethyLight). Preferential methylation in the serum DNA of gastric cancer patients was noted in APC (17%), E-cadherin (13%), hMLH1 (41%) and TIMP3 (17%) genes. Moreover, patients with stages III/IV diseases tended to have higher concentrations of methylated APC (P = 0.08), TIMP3 (P = 0.005) and hMLH1 (P = 0.03) in the serum. In all, 33 cancers (55%) had methylation detected in the serum in at least one of these four markers, while three normal subjects had methylation detected in the serum (specificity 86%). The combined use of APC and E-cadherin methylation markers identified a subgroup of cancer patients with worse prognosis (median survival 3.3 vs 16.1 months, P = 0.006). These results suggest that the detection of DNA methylation in the serum may carry both diagnostic and therapeutic values in gastric cancer patients. © 2005 Cancer Research UK.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjcen_US
dc.relation.ispartofBritish Journal of Canceren_US
dc.subjectGastric cancer promoter hypermethylation-
dc.subjectOncogenes-
dc.subjectTumour suppressor genes-
dc.subject.meshAdenocarcinoma - Blood - Diagnosis - Geneticsen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshDna Methylationen_US
dc.subject.meshDna, Neoplasm - Blood - Geneticsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGenes, Tumor Suppressor - Physiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOncogenes - Physiologyen_US
dc.subject.meshPrognosisen_US
dc.subject.meshPromoter Regions, Geneticen_US
dc.subject.meshStomach Neoplasms - Blood - Diagnosis - Geneticsen_US
dc.titlePotential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric canceren_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/sj.bjc.6602636en_US
dc.identifier.pmid15942635-
dc.identifier.scopuseid_2-s2.0-22044441872en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-22044441872&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume92en_US
dc.identifier.issue12en_US
dc.identifier.spage2190en_US
dc.identifier.epage2194en_US
dc.identifier.isiWOS:000229794400016-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridTo, KF=7101911940en_US
dc.identifier.scopusauthoridChu, ESH=8631130300en_US
dc.identifier.scopusauthoridChan, MWY=7402597788en_US
dc.identifier.scopusauthoridBai, AHC=7006523130en_US
dc.identifier.scopusauthoridNg, EKW=7201647539en_US
dc.identifier.scopusauthoridChan, FKL=7202586434en_US
dc.identifier.scopusauthoridSung, JJY=35405352400en_US
dc.identifier.citeulike221471-
dc.identifier.issnl0007-0920-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats